Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension

The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.

Condition or disease : hypertension Intervention/treatment Drug : AD-209-H Drug : AD-209-M Drug : AD-209-L Drug : Placebo Drug : Amlodipine Drug : Telmisartan Phase : Phase 2

Inclusion Criteria:

• Signed informed consent
• Other inclusions applied

Exclusion Criteria:

• orthostatic hypotension with symptom
• Other exclusions applied